This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
19 October 2023
We speak to Jan van Meerbeeck, Honorary Professor of Pulmonology, Antwerp University and Ghent University, and Senior Consultant Thoracic Oncologist, Antwerp University Hospital, Belgium
What led you to work in the field of lung cancer?
When I started as an internal medicine specialist and pulmonologist 40 years ago, there was an unmet need for care for people with lung cancer. Due to this gap in care, I carried out my PhD on the presentation of lung cancer in Belgium. I specialised in this field to help improve lung cancer outcomes and move research forward.
What does an average workday look like for you?
I have retired from working clinically, so now spend my time doing research and consultancy. My current research focus is on the implementation of lung cancer screening in Belgium.
I am also heavily involved in wider lung cancer policy, sitting on many committees and assemblies. I am currently the chair of the European Respiratory Society’s Thoracic Oncology Assembly and a member of their mesothelioma guideline committee.
What is working well in Belgium, and what could be improved?
In Belgium, healthcare is split between different authorities which makes decision-making complicated and slows down the process of implementing screening. There are complex issues with healthcare financing that also hinder the implementation of a lung cancer screening programme.
What motivated you to join the Lung Cancer Policy Network?
A desire to network and collaborate with other lung cancer professionals to help shape policy and improve the implementation of lung cancer screening programmes.
What would you like to see from the Network as it develops?
More of an emphasis on synthesising and disseminating practical tools or documents to engage and persuade health authorities and politicians to spend on lung cancer prevention and screening.
What changes would you like to see in lung cancer care on a global level?
More academic research in the areas of lung cancer screening implementation, biomarkers for early diagnosis and mesothelioma treatment.
There should also be a move to concentrate care in expert centres.
What recent research do you think is the most interesting or exciting?
I see the most promise in immunotherapy, targeted agents and low-dose computed tomography (LDCT) screening. Targeted agents have the potential to turn metastatic lung cancer into a chronic disease that can be managed by daily medication with minimal side effects.
Outside of work, what do you spend your time doing?
Reading historical novels and travelling.
Recent news
News
Network produces recommendations for lung cancer screening in Asia Pacific
The Lung Cancer Policy Network recently hosted a collaborative workshop with the Asia Pacific Coalition Against Lung Cancer during the Asia Conference on Lung Cancer.
Blog
2024 reflections: a year of progress across the global lung cancer community
More people have access to LDCT screening than ever before. This year, four more countries have made a formal commitment to implement LDCT screening for lung cancer, and several implementation studies are under way.
Case study
Building evidence to inform future roll-out of lung cancer screening in Estonia
We examine the key evidence used to inform the development of a national screening programme for lung cancer in Estonia from 2021 to date.